+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Cachexia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023 - Product Image

Cancer Cachexia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

  • ID: 4850442
  • Report
  • October 2019
  • Region: Global
  • 148 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • ANI Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Fresenius SE & Co. KGaA
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
Global Cancer Cachexia Therapeutics Market: About this market
The cancer cachexia therapeutics market analysis considers sales from progestogens, corticosteroids, combination therapies, and other therapeutic products. Our study also finds the sales of cancer cachexia therapeutics in Asia, Europe, North America, and ROW. In 2018, the progestogens segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the effective and safest option for the palliative treatment of cancer cachexia will play a significant role in the progestogens segment to maintain its market position. Also, our global cancer cachexia therapeutics market report looks at factors such as high prevalence and incidence of cancer cachexia, strong pipeline landscape, and rising geriatric population. However, lack of approved therapies to treat cancer cachexia, side effects associated with corticosteroids, and stringent regulatory guidelines may hamper the growth of the cancer cachexia therapeutics industry over the forecast period.

Global Cancer Cachexia Therapeutics Market: Overview

High prevalence and incidence of cancer cachexia
Globally, the cancer burden is high, which can be attributed to population growth, poverty, infections, and unhealthy lifestyle habits, among others. The high prevalence and incidence of cancer are directly proportional to the number of cancer cachexia cases. The large patient cohort requires multiple physician visits and numerous medications for the treatment of cancer cachexia, which is consequently driving market growth. Cancer cachexia is a complex syndrome, which is characterized by muscle wasting, anorexia, fatigue, and anemia, leading to progressive functional damage, and is estimated to affect over half of all cancer patients. There is a huge cancer patient population in Asia, with China, India, and Japan being among the top five countries with the highest incidence of cancer. Thus, the high prevalence and incidence of the disease will lead to the expansion of the global cancer cachexia therapeutics market at a CAGR of almost 6% during the forecast period.

Rising preference for novel therapies
The lack of approved drugs for the treatment of cachexia in patients and administration of monotherapy with progestogens and corticosteroids have driven cancer patients and physicians to opt for alternative therapeutic approaches. Consequently, a combination of multiple medical and nutritional therapeutic interventions are gaining traction in the market. These therapeutics offer better safety and efficacy profiles. The increasing R&D by companies and the availability of novel drugs for the treatment of cancer cachexia facilitates their adoption among patients. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global cancer cachexia therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer cachexia therapeutics manufacturers, that include AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the cancer cachexia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • ANI Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Fresenius SE & Co. KGaA
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Progestogens - Market size and forecast 2018-2023
  • Corticosteroids - Market size and forecast 2018-2023
  • Combination therapies - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Growing awareness about supportive care for cancer patients
  • Increasing healthcare expenditure
  • Rising preference for novel therapies
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • ANI Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Progestogens - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Progestogens - Year-over-year growth 2019-2023 (%)
Exhibit 22: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 24: Combination therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Combination therapies - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AbbVie Inc. - Vendor overview
Exhibit 53: AbbVie Inc. - Business segments
Exhibit 54: AbbVie Inc. - Organizational developments
Exhibit 55: AbbVie Inc. - Geographic focus
Exhibit 56: AbbVie Inc. - Key offerings
Exhibit 57: AbbVie Inc. - Key customers
Exhibit 58: ANI Pharmaceuticals Inc. - Vendor overview
Exhibit 59: ANI Pharmaceuticals Inc. - Business segments
Exhibit 60: ANI Pharmaceuticals Inc. - Organizational developments
Exhibit 61: ANI Pharmaceuticals Inc. - Geographic focus
Exhibit 62: ANI Pharmaceuticals Inc. - Key offerings
Exhibit 63: ANI Pharmaceuticals Inc. - Key customers
Exhibit 64: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 65: Bristol-Myers Squibb Co. - Business segments
Exhibit 66: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 67: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 68: Bristol-Myers Squibb Co. - Key offerings
Exhibit 69: Bristol-Myers Squibb Co. - Key customers
Exhibit 70: Fresenius SE & Co. KGaA - Vendor overview
Exhibit 71: Fresenius SE & Co. KGaA - Business segments
Exhibit 72: Fresenius SE & Co. KGaA - Organizational developments
Exhibit 73: Fresenius SE & Co. KGaA - Geographic focus
Exhibit 74: Fresenius SE & Co. KGaA - Segment focus
Exhibit 75: Fresenius SE & Co. KGaA - Key offerings
Exhibit 76: Fresenius SE & Co. KGaA - Key customers
Exhibit 77: Hikma Pharmaceuticals Plc - Vendor overview
Exhibit 78: Hikma Pharmaceuticals Plc - Business segments
Exhibit 79: Hikma Pharmaceuticals Plc - Organizational developments
Exhibit 80: Hikma Pharmaceuticals Plc - Geographic focus
Exhibit 81: Hikma Pharmaceuticals Plc - Segment focus
Exhibit 82: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 83: Hikma Pharmaceuticals Plc - Key customers
Exhibit 84: Merck & Co. Inc. - Vendor overview
Exhibit 85: Merck & Co. Inc. - Business segments
Exhibit 86: Merck & Co. Inc. - Organizational developments
Exhibit 87: Merck & Co. Inc. - Geographic focus
Exhibit 88: Merck & Co. Inc. - Segment focus
Exhibit 89: Merck & Co. Inc. - Key offerings
Exhibit 90: Merck & Co. Inc. - Key customers
Exhibit 91: Mylan NV - Vendor overview
Exhibit 92: Mylan NV - Product segments
Exhibit 93: Mylan NV - Organizational developments
Exhibit 94: Mylan NV - Geographic focus
Exhibit 95: Mylan NV - Segment focus
Exhibit 96: Mylan NV - Key offerings
Exhibit 97: Mylan NV - Key customers
Exhibit 98: Pfizer Inc. - Vendor overview
Exhibit 99: Pfizer Inc. - Business segments
Exhibit 100: Pfizer Inc. - Organizational developments
Exhibit 101: Pfizer Inc. - Geographic focus
Exhibit 102: Pfizer Inc. - Segment focus
Exhibit 103: Pfizer Inc. - Key offerings
Exhibit 104: Pfizer Inc. - Key customers
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 108: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 109: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 110: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • ANI Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Fresenius SE & Co. KGaA
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
The following companies as the key players in the global cancer cachexia therapeutics market: AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising preference for novel therapies.”

According to the report, one of the major drivers for this market is the high prevalence and incidence of cancer cachexia.

Further, the report states that one of the major factors hindering the growth of this market is the stringent regulatory guidelines.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • ANI Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll